At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...
Cystic fibrosis drug developer Sionna rises on trading debut
Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharma focused on developing cystic fibrosis therapies, opened well above its initial public offering price on Friday in its first trading ...
3 questions for Josh Kraft
HAPPY BIRTHDAY — to David Edelman, Ropes & Gray’s Abby Cable; former Gov. Charlie Baker senior adviser and the NCAA’s Tim ...
Yahoo Finance4d
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.37, demonstrating a +1.88% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...
Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
Benzinga.com4d
Vertex Pharmaceuticals Unusual Options Activity
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 10 unusual trades. Delving into the ...
Yahoo Finance6d
Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx ...